印记基因PHLDA2表达与骨肉瘤辐射敏感性的研究

Study of imprinted gene PHLDA2 expression and radiosensitivity in osteosarcoma patients

目的探讨印记基因PHLDA2在骨肉瘤放疗疗效评估中的意义。方法采用免疫组织化学S-P法和RT-PCR方法在36例放射治疗后的骨肉瘤组织及其配对的癌旁组织中检测PHLDA2分子的表达,并结合临床病例参数及辐射敏感性探讨PHLDA2表达的意义。结果放射治疗后的骨肉瘤组织中PHLDA2分子mRNA和蛋白的表达一致,明显低于配对的癌旁组织,差异具有统计学意义(P<0.05);辐射缓解组中PHLDA2的表达阳性率高,与辐射抵抗组差异有统计学意义(P<0.05);但PHLDA2表达与骨肉瘤患者的性别、年龄、病理分型不相关,差异无统计学意义(P>0.05)。结论骨肉瘤组织中PHLDA2的表达显著降低,其表达可作为一种骨肉瘤放疗疗效评估的参考指标,值得在临床上推广运用。

Objective To study imprinted gene PHDLA2 expression for assessment of radiosensitivity in the tissues of human osteosarcoma. Methods Immunohistochemical SP method and RT-PCR method were used to detect the expression of PHLDA2 in 36 cases of osteosarcoma and their paired after radiotherapy, and analyze the relationship between PHLDA2 expression and clinical parameters and radiosensitivity. Results The mRNA expression of PHLDA2 was consistent with the expression of protein in osteosarcoma, which was significantly lower than the expression of paired （P 〈 0. 05 ）; meanwhile the positive expressed rate of PHLDA2 in radiosensitive group was significantly higher than that of radioresistant group （ P 〈 0.05）. The PHLDA2 expression was not irrelevant with the gender, age and pathological typing of osteosarcoma （ P 〉 0.05 ）. Conclusions The expression of PHLDA2 significantly reduce in osteosarcoma, which play an important role in evaluating the radiosensitivity of osteosarcoma.